Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:DNANASDAQ:MNMDNASDAQ:NLTXNASDAQ:TRML On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNAGinkgo Bioworks$8.53-0.5%$7.78$5.00▼$17.46$501.62M1.251.46 million shs987,316 shsMNMDMind Medicine (MindMed)$7.05-0.6%$6.77$4.70▼$10.44$532.65M2.521.35 million shs1.27 million shsNLTXNeoleukin Therapeutics$17.76-3.0%$16.65$2.03▼$14.36$166.91M1.1150,104 shs108,535 shsTRMLTourmaline Bio$16.64-1.1%$16.73$11.56▼$29.79$427.40M2.04274,186 shs294,434 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNAGinkgo Bioworks0.00%-4.54%+24.44%+16.81%-59.64%MNMDMind Medicine (MindMed)0.00%-1.67%-0.28%+4.91%-3.69%NLTXNeoleukin Therapeutics-2.95%-10.12%-4.26%+24.98%-41.42%TRMLTourmaline Bio0.00%-15.45%+8.97%-2.97%+7.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNAGinkgo Bioworks0.8538 of 5 stars0.81.00.00.03.12.51.3MNMDMind Medicine (MindMed)1.4097 of 5 stars3.60.00.00.01.40.80.6NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATRMLTourmaline Bio1.9965 of 5 stars3.53.00.00.00.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNAGinkgo Bioworks 1.67Reduce$5.77-32.42% DownsideMNMDMind Medicine (MindMed) 3.27Buy$25.50261.70% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/ATRMLTourmaline Bio 3.00Buy$49.33196.47% UpsideCurrent Analyst Ratings BreakdownLatest NLTX, TRML, MNMD, and DNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/5/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.005/5/2025TRMLTourmaline BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/23/2025TRMLTourmaline BioChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$70.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNAGinkgo Bioworks$227.04M2.20N/AN/A$13.17 per share0.65MNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/ATRMLTourmaline BioN/AN/AN/AN/A$11.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNAGinkgo Bioworks-$547.03M-$9.16N/AN/AN/A-198.84%-52.35%-27.14%8/14/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.29N/AN/AN/AN/A-40.33%-32.13%8/12/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/ATRMLTourmaline Bio-$73.21M-$3.21N/AN/AN/AN/A-26.75%-26.11%8/6/2025 (Estimated)Latest NLTX, TRML, MNMD, and DNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A5/6/2025Q1 2025DNAGinkgo Bioworks-$1.23-$1.58-$0.35-$1.68$38.70 million$48.32 million5/2/2025Q1 2025TRMLTourmaline Bio-$0.91-$0.89+$0.02-$0.89N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNAGinkgo BioworksN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/ATRMLTourmaline BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNAGinkgo BioworksN/A4.884.88MNMDMind Medicine (MindMed)0.107.277.27NLTXNeoleukin TherapeuticsN/A15.3315.33TRMLTourmaline BioN/A33.8733.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNAGinkgo Bioworks78.63%MNMDMind Medicine (MindMed)27.91%NLTXNeoleukin Therapeutics52.37%TRMLTourmaline Bio91.89%Insider OwnershipCompanyInsider OwnershipDNAGinkgo Bioworks9.72%MNMDMind Medicine (MindMed)2.45%NLTXNeoleukin Therapeutics1.58%TRMLTourmaline Bio13.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNAGinkgo Bioworks64058.53 million52.84 millionOptionableMNMDMind Medicine (MindMed)4075.55 million73.70 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataTRMLTourmaline Bio4425.68 million22.35 millionOptionableNLTX, TRML, MNMD, and DNA HeadlinesRecent News About These CompaniesCantor Fitzgerald Weighs in on Tourmaline Bio FY2026 EarningsJune 11, 2025 | marketbeat.comTwo Sigma Investments LP Sells 21,904 Shares of Tourmaline Bio, Inc. (NASDAQ:TRML)June 10, 2025 | marketbeat.comTourmaline Bio Elects Directors and Ratifies AuditorJune 6, 2025 | tipranks.comTourmaline Bio, Inc. (NASDAQ:TRML) Shares Bought by Bank of America Corp DEJune 6, 2025 | marketbeat.comTourmaline Bio (NASDAQ:TRML) Trading Up 7.2% - Here's What HappenedJune 5, 2025 | marketbeat.comTourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of "Buy" from BrokeragesMay 31, 2025 | marketbeat.comH.C. Wainwright maintains $50 target on Tourmaline Bio stockMay 29, 2025 | uk.investing.comH.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 ResultsMay 29, 2025 | msn.comMillennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML)May 28, 2025 | marketbeat.comLeerink Partnrs Comments on Tourmaline Bio FY2026 EarningsMay 27, 2025 | marketbeat.com29,844 Shares in Tourmaline Bio, Inc. (NASDAQ:TRML) Purchased by Rafferty Asset Management LLCMay 25, 2025 | marketbeat.comBMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)May 23, 2025 | msn.comWexford Capital LP Purchases New Position in Tourmaline Bio, Inc. (NASDAQ:TRML)May 22, 2025 | marketbeat.comTourmaline shares waver as investors mull mid-stage pacibekitug dataMay 21, 2025 | thepharmaletter.comTourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease winMay 21, 2025 | fiercebiotech.comTourmaline Bio posts mid-stage data for anti-inflammatory agentMay 21, 2025 | msn.comTourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 InhibitionMay 20, 2025 | seekingalpha.comTourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025May 19, 2025 | globenewswire.comTourmaline Bio Reports Q1 2025 Financial ResultsMay 7, 2025 | tipranks.comWhy Tourmaline Bio, Inc.’s (TRML) Stock Is Down 7.00%May 3, 2025 | aaii.comTourmaline Bio, Inc.: Tourmaline Bio Reports First Quarter 2025 Financial Results and Recent Business HighlightsMay 3, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNLTX, TRML, MNMD, and DNA Company DescriptionsGinkgo Bioworks NYSE:DNA$8.53 -0.05 (-0.55%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$8.37 -0.16 (-1.91%) As of 06/20/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.Mind Medicine (MindMed) NASDAQ:MNMD$7.05 -0.04 (-0.56%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$7.04 -0.01 (-0.14%) As of 06/20/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Neoleukin Therapeutics NASDAQ:NLTX$17.76 -0.54 (-2.95%) As of 06/20/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Tourmaline Bio NASDAQ:TRML$16.64 -0.19 (-1.13%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$16.64 0.00 (0.00%) As of 06/20/2025 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
